MADISON, Wis., May 1, 2017 /PRNewswire/ -- Exact Sciences
Corp. (Nasdaq: EXAS) today announced that the company will
participate in the Bank of America Merrill Lynch 2017 Healthcare
Conference in Las Vegas.
Kevin Conroy, Exact Sciences'
chairman and CEO, and Jeff Elliott,
the company's chief financial officer, will participate in a
fireside chat at the conference on Tuesday,
May 16 at 11:20 a.m. PT.
A live webcast of the event will be available through the
company's website at www.exactsciences.com. An archived webcast
will be available following the conclusion of the fireside
chat.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company
focused on the early detection and prevention of the deadliest
forms of cancer. The company has exclusive intellectual property
protecting its noninvasive, molecular screening technology for the
detection of colorectal cancer. Cologuard is included in the
American Cancer Society's (2014) colorectal cancer screening
guidelines and the recommendations of the U.S. Preventive Services
Task Force (2016). Stool DNA is included in the combined screening
guidelines of the American Cancer Society/U.S. Multi-Society Task
Force/American College of Radiology (2008) and the American College
of Gastroenterology guidelines (2009).
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
that are intended to be covered by the "safe harbor" created by
those sections. Forward-looking statements, which are based on
certain assumptions and describe our future plans, strategies and
expectations, can generally be identified by the use of
forward-looking terms such as "believe," "expect," "may," "will,"
"should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. All statements other than
statements of historical facts included in this news release
regarding our strategies, prospects, financial condition,
operations, costs, plans and objectives are forward-looking
statements. Examples of forward-looking statements include, among
others, statements we make regarding expected future operating
results, anticipated results of our sales and marketing efforts,
expectations concerning payer reimbursement and the anticipated
results of our product development efforts. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs,
expectations and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results and financial condition may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
and financial condition to differ materially from those indicated
in the forward-looking statements include, among others, the
following: our ability to successfully and profitably market our
products and services; the acceptance of our products and services
by patients and healthcare providers; our ability to meet demand
for our products and services; the willingness of health insurance
companies and other payers to cover Cologuard and reimburse us for
our performance of the Cologuard test; the amount and nature of
competition from other cancer screening products and services; the
effects of the adoption, modification or repeal of any healthcare
reform law, rule, order, interpretation or policy; the effects of
changes in healthcare pricing, coverage and reimbursement;
recommendations, guidelines and quality metrics issued by various
organizations such as the U.S. Preventive Services Task Force, the
American Cancer Society, and the National Committee for Quality
Assurance regarding cancer screening or our products and services;
our ability to successfully develop new products and services; our
success establishing and maintaining collaborative, licensing and
supplier arrangements; our ability to maintain regulatory approvals
and comply with applicable regulations; and the other risks and
uncertainties described in the Risk Factors and in Management's
Discussion and Analysis of Financial Condition and Results of
Operations sections of our most recently filed Annual Report on
Form 10-K and our subsequently filed Quarterly Report(s) on Form
10-Q. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
Megan
Reiss
Exact Sciences Corp.
Investor Relations Analyst
meganreiss@exactsciences.com
608-535-8815
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/exact-sciences-to-participate-in-bank-of-america-merrill-lynch-healthcare-conference-300448429.html
SOURCE EXACT SCIENCES CORP